PT - JOURNAL ARTICLE AU - D’Auria, Francesca AU - Santo, Danilo Flavio TI - Bubbles help in troubles: contrast-enhanced ultrasound (CEUS) as predictor of recurrence for TIA/stroke in low-grade internal carotid artery stenosis AID - 10.1101/2024.04.17.24306003 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.17.24306003 4099 - http://medrxiv.org/content/early/2024/04/19/2024.04.17.24306003.short 4100 - http://medrxiv.org/content/early/2024/04/19/2024.04.17.24306003.full AB - Introduction Contrast-enhanced ultrasound (CEUS) allows to visualize atherosclerotic plaque neo-vessels which are the hallmark of carotid plaque instability.Aim Aim of our prospective study was to check the correlation between carotid CEUS analysis and the recurrence of TIA/stroke in patients with a previous recent TIA/stroke and neurological impairment congruent with the vascular stenosis.Materials and Methods From November 2021 to May 2023, 62 consecutive patients (mean age 73.8 +/- 12.2, female 51) with a TIA/stroke in the previous 30 days, underwent carotid ultrasound and carotid CEUS in outpatients setting after 10 days from the acute event. Inclusion criteria was one atherosclerotic plaque inside the internal carotid artery, congruent with symptoms, which was causing a stenosis less than 50% (low-grade stenosis). Carotid plaque neovascularization scoring method was: score 0: no visible microbubbles within the plaque (A); score 1: minimal microbubbles confined to periadventitial (B); and score 2: microbubbles present throughout the plaque core (C). During the six-month follow-up, we checked TIA/stroke recurrences. A multivariable logistic regression analysis was performed.Results In our series, 22% of patients have CEUS score 0, 35% CEUS score 1, and 43% CEUS score 2. At six-month follow-up we found 21% TIA/stroke recurrences in CEUS score 2, despite of the ongoing best medical therapy as per guidelines. In Cox regression analysis, CEUS-detected neovascularization was independently associated with TIA/stroke recurrence (hazard ratio, 5.37; 95% confidence interval, 1.36–2.31).Conclusions Plaque neovascularization, detected by CEUS, is an independent predictor of TIA/stroke recurrence at six-month follow-up in patients with carotid atherosclerosis despite of low-grade stenosis.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study is not registered on international trial registry because it is only a pilot project protocol with internal ethical committee registration (Regione Campania - Comitato Etico - University of Salerno, Italy).Funding StatementNo sponsor or external fund were used to conduct this independent search.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Azienda Ospedaliera San Giovanni di Dio - Ruggi d'Aragona of Salerno - University of Salerno - Ethical Committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe collected data are available for further analysis and FDA is the responsible for data custody. The study compliances with ethical standards. Each patient signed the specific informed consent to be enrolled in this research and authorized to publish the data in anonymous mode for search purpose only.